Cancer Research Donn Young  Sign up for Cancer Research eTOC's
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

Cancer Research 69, 5901, July 15, 2009. Published Online First June 30, 2009;
doi: 10.1158/0008-5472.CAN-08-4816
© 2009 American Association for Cancer Research

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Supplementary Data
Right arrow All Versions of this Article:
0008-5472.CAN-08-4816v1
69/14/5901    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Google Scholar
Right arrow Articles by Corthay, A.
Right arrow Articles by Bogen, B.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Corthay, A.
Right arrow Articles by Bogen, B.

Immunology

Secretion of Tumor-Specific Antigen by Myeloma Cells Is Required for Cancer Immunosurveillance by CD4+ T Cells

Alexandre Corthay, Katrin U. Lundin, Kristina Berg Lorvik, Peter O. Hofgaard and Bjarne Bogen

Center for Immune Regulation, Institute of Immunology, University of Oslo and Oslo University Hospital, Rikshospitalet, Oslo, Norway

Requests for reprints: Alexandre Corthay, University of Oslo, Institute of Immunology, Rikshospitalet, 0027 Oslo, Norway. Phone: 47-23-07-35-08; Fax: 47-23-07-35-10; E-mail: Alexandre.Corthay{at}medisin.uio.no.

Key Words: Cancer immunosurveillance • CD4+ T cells • Myeloma • Secretion • Tumor-specific antigen

Tumor-specific CD4+ T cells orchestrate the adaptive immune responses against cancer. We have previously shown that CD4+ T cells recognize MHC class II–negative myeloma cells indirectly by collaborating with tumor-infiltrating macrophages. We, here, hypothesize that this critical step may be dependent on secretion of tumor-specific antigens by cancer cells. This was investigated using T-cell receptor–transgenic mice, in which CD4+ T cells mediate rejection of syngeneic MOPC315 myeloma cells. We analyzed the immune response against myeloma cell variants, which either secrete or retain intracellularly a tumor-specific idiotypic (Id) antigen. Our results reveal that CD4+ T cells helped by macrophages are capable of detecting nonsecreted tumor antigens from MHC class II–negative cancer cells. However, Id secretion was required for successful myeloma immunosurveillance. Antigen secretion resulted in stronger priming of naive myeloma-specific CD4+ T cells in tumor-draining lymph nodes. Secretion of antigen by at least some cancer cells within a tumor was shown to facilitate immunosurveillance. Treatment by local injection of purified tumor-specific antigen successfully enhanced immunity against nonsecreting myeloma cells. Collectively, the data indicate that antigen concentration within the tumor extracellular matrix must reach a certain threshold to allow successful cancer immunosurveillance by CD4+ T cells. [Cancer Res 2009;69(14):5901–7]







HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2009 by the American Association for Cancer Research.